Amoy Diagnostics Co Ltd
SZSE:300685

Watchlist Manager
Amoy Diagnostics Co Ltd Logo
Amoy Diagnostics Co Ltd
SZSE:300685
Watchlist
Price: 24.8 CNY -4.62% Market Closed
Market Cap: 9.7B CNY
Have any thoughts about
Amoy Diagnostics Co Ltd?
Write Note

Amoy Diagnostics Co Ltd
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amoy Diagnostics Co Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Amoy Diagnostics Co Ltd
SZSE:300685
Non-Reccuring Items
-ÂĄ36.7k
CAGR 3-Years
73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Non-Reccuring Items
-ÂĄ248k
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Non-Reccuring Items
-ÂĄ222.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Non-Reccuring Items
-ÂĄ1.2m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Non-Reccuring Items
-ÂĄ1.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Non-Reccuring Items
-ÂĄ106.9k
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Amoy Diagnostics Co Ltd
Glance View

Market Cap
9.9B CNY
Industry
Biotechnology

Amoy Diagnostics Co., Ltd. engages in the research, development, production and sale of tumour precision medical molecular diagnostic products. The company is headquartered in Xiamen, Fujian and currently employs 1,096 full-time employees. The company went IPO on 2017-08-02. The firm provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The firm also provides data software to capture and analyze gene sequencing data. The firm provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.

Intrinsic Value
28 CNY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Amoy Diagnostics Co Ltd's Non-Reccuring Items?
Non-Reccuring Items
-36.7k CNY

Based on the financial report for Sep 30, 2024, Amoy Diagnostics Co Ltd's Non-Reccuring Items amounts to -36.7k CNY.

What is Amoy Diagnostics Co Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
73%

Over the last year, the Non-Reccuring Items growth was 96%. The average annual Non-Reccuring Items growth rates for Amoy Diagnostics Co Ltd have been 73% over the past three years .

Back to Top